Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;56(12):2940-2947.
doi: 10.1038/s41409-021-01431-6. Epub 2021 Aug 25.

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

Lan-Ping Xu  1 , Pei-Hua Lu  2 , De-Pei Wu  3 , Zi-Min Sun  4 , Qi-Fa Liu  5 , Ming-Zhe Han  6 , Xi Zhang  7 , Yong-Ping Song  8 , Xian-Min Song  9 , Jian-da Hu  10 , He Huang  11 , Yong-Rong Lai  12 , Ding-Ming Wan  13 , Jing Chen  14 , Chun-Fu Li  15 , Ling-Hui Xia  16 , Jing-Bo Wang  17 , Dai-Hong Liu  18 , Xiao-Jun Huang  19 ; Chinese Blood and Marrow Transplantation Registry Group
Affiliations

Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group

Lan-Ping Xu et al. Bone Marrow Transplant. 2021 Dec.

Abstract

Between 2008 and 2019, 58,914 hematopoietic stem cell transplantations (HSCTs) were reported to the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) throughout China. In this report, we focus on 2019 data and describe current trends in HSCT in China. There was continued growth in transplant activity in China, with a rapid increase in haploidentical HSCT. In 2019, a total of 12,323 cases of HSCT were reported from 149 transplant teams, 78% (9597 cases) were allogeneic HSCTs. Haploidentical donor (HID) HSCT accounted for 60% (5771 cases) of allogeneic HSCT. The most common indications for allogeneic HSCT for malignant disease were acute myeloid leukemia (AML) (37%) and acute lymphoblastic leukemia (ALL) (24%), and the largest proportion of non-malignant diseases comprised aplastic anemia (AA) (13%). Multiple stem cell source composed 70% of HID and 28% of MSD, which was typical in China. The BuCy based regimen (59%) was the most popular conditioning regimen for allogeneic HSCT, followed by the BuFlu based regimen (23%) and TBI-based regimen (12%). This survey clearly shows comprehensive information about the current state and recent trends for HSCT in China. Further efforts should be made to obtain detailed information.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1. HSCT trend in China during 2008–2019.
a Annual number of HSCT. b Annual number of allogeneic HSCT based on donor type. c Annual trend of absolute numbers of disease indications for allogeneic HSCT.
Fig. 2
Fig. 2. Distribution of ages of HSCT recipients in China 2019.
Distribution of ages of HSCT recipients in China 2019.
Fig. 3
Fig. 3. Distribution of disease indications for HSCT in China 2019.
a Relative proportion of allogeneic HSCT. b Relative proportion of autologous HSCT. c Proportions of indication for pediatric patients. d Proportion of indication for elderly patients.
Fig. 4
Fig. 4. Annual trend of absolute number of HSCT for severe aplastic anemia based on donor type.
Annual trend of absolute number of HSCT for severe aplastic anemia based on donor type.
Fig. 5
Fig. 5. Distribution of conditioning regimen of allogeneic HSCT in China 2019.
a Relative proportion of conditioning regimen of allogeneic HSCT. b Relative proportion of conditioning regimen of malignant disease. c Relative proportion of conditioning regimen of non-malignant disease.
See this image and copyright information in PMC

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. doi: 10.1056/NEJMra052638. - DOI - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. doi: 10.1001/jama.2010.491. - DOI - PMC - PubMed
    1. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54:1525–52. doi: 10.1038/s41409-019-0516-2. - DOI - PubMed
    1. Xu LP, Chen H, Chen J, Han MZ, Huang H, Kai YY, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11:33. doi: 10.1186/s13045-018-0564-x. - DOI - PMC - PubMed
    1. Worldwide Network for Blood and Marrow Transplantation. WBMT 2016 Survey Slides. 2020. https://www.wbmt.org/.

Publication types